We are live on ! Find out more
CRVO icon

CervoMed

1.55 USD
-0.12
7.19%
At close Updated Nov 17, 2:45 PM EST
1 day
-7.19%
5 days
10.71%
1 month
-32.9%
3 months
-40.61%
6 months
-49.01%
Year to date
-80.1%
1 year
-81.12%
5 years
-94.74%
10 years
-99.97%
 

About: CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Employees: 15

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
22 hours ago
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
Neutral
GlobeNewsWire
8 days ago
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Presentation and publication of clinical and biomarker data, regulatory developments,  and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies Rapidly advancing neflamapimod for the treatment of nonfluent variant primary progressive aphasia; 24-week biomarker data selected for presentation at the 19 th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD 2026) BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the third quarter ended September 30, 2026, and provided corporate updates. “The Company believes that the neflamapimod clinical development program has been significantly de-risked through the presentation and publication of compelling, supportive datasets throughout this year and the ability to advance the 100mg BID dosing regimen, strengthening its position as a potential therapeutic for dementia with Lewy bodies and other devastating neurodegenerative disorders,” stated John Alam, MD, Chief Executive Officer of CervoMed.
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Neutral
GlobeNewsWire
19 days ago
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer's Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Neutral
Benzinga
1 month ago
CervoMed Shows Progress in Treating Rare Aphasia Condition
CervoMed Inc. (NASDAQ:CRVO) reported early results from its Phase 2a clinical study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
CervoMed Shows Progress in Treating Rare Aphasia Condition
Neutral
GlobeNewsWire
1 month ago
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Neutral
GlobeNewsWire
1 month ago
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Neutral
GlobeNewsWire
2 months ago
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Neutral
GlobeNewsWire
2 months ago
CervoMed to Participate in September Investor Conferences
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:
CervoMed to Participate in September Investor Conferences
Neutral
GlobeNewsWire
3 months ago
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Neutral
GlobeNewsWire
3 months ago
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
Price charts implemented using Lightweight Charts™